Global Meglumine Diatrizoate Injection Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Meglumine Diatrizoate Injection Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Meglumine Diatrizoate Injection market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The major consumer markets for Meglumine Diatrizoate Injection are North America, Europe and the Asia-Pacific region. With the gradual recovery of the global economy after the COVID-19 outbreak and the return of major economies to normal, the medical industry will see certain growth. As the global medical level continues to improve, more and more hospitals and clinics are able to perform MRI and CT imaging. Therefore, the demand for Meglumine Diatrizoate Injection will increase in the foreseeable time.

Meglumine injection, indicated as this contrast agent for intravenous and retrograde urography; Cerebral, thoracic, abdominal and limbs angiography, venography and CT; It can also be used for arthrography, fistula imaging, hysterosalpingography, endoscopic retrograde cholangiopancreatography (ERCP), sialography, and other tests. Meglumine injection should not be used in selective coronary angiography. It should not be used for myelography, ventriculography, or cisternography as it may induce neurotoxic symptoms.

This report is a detailed and comprehensive analysis for global Meglumine Diatrizoate Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Meglumine Diatrizoate Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (US$/Bottle), 2018-2029

Global Meglumine Diatrizoate Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (US$/Bottle), 2018-2029

Global Meglumine Diatrizoate Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (US$/Bottle), 2018-2029

Global Meglumine Diatrizoate Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (US$/Bottle), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Meglumine Diatrizoate Injection

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Meglumine Diatrizoate Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AdvaCare Pharma, Shanghai Xudong Haipu Pharmaceutical, Hunan Hansen Pharmaceutical, Shanghai Bracco Sine Pharmaceutical and Lunan Pharmaceutical and etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Meglumine Diatrizoate Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
1ml/0.3g
20ml/15.2g
20ml/12g
100ml/60g

Market segment by Application
Hospital
Clinic
Pharmacy

Major players covered
AdvaCare Pharma
Shanghai Xudong Haipu Pharmaceutical
Hunan Hansen Pharmaceutical
Shanghai Bracco Sine Pharmaceutical
Lunan Pharmaceutical
Xi'an Hanfeng Pharmaceutical

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Meglumine Diatrizoate Injection product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Meglumine Diatrizoate Injection, with price, sales, revenue and global market share of Meglumine Diatrizoate Injection from 2018 to 2023.

Chapter 3, the Meglumine Diatrizoate Injection competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Meglumine Diatrizoate Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Meglumine Diatrizoate Injection market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Meglumine Diatrizoate Injection.

Chapter 14 and 15, to describe Meglumine Diatrizoate Injection sales channel, distributors, customers, research findings and conclusion.